These growth stocks are trading at major discounts

Are these two companies cheap enough to merit purchase right now?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Many investors may be surprised to find out that there are still a number of shares trading at large discounts to their intrinsic values. That’s despite the FTSE 100 having reached a record high this year, which has pushed many stocks to higher valuations than they have achieved in recent years. However, that doesn’t mean all companies are overpriced. In fact, here are two stocks which appear to be cheap based on their future prospects. But does that mean they are worth buying today?

Impressive update

Reporting on Monday was service-led niche pharmaceutical developer, Quantum Pharma (LSE: QP). The company announced the disposal of Total Medication Management Services, which is a homecare dispensary and delivery business which trades as Biodose Services. The disposal is another significant step in the transition of the business as it seeks to focus on its core Specials and Niche Pharmaceuticals divisions. The initial cash consideration on disposal will be £1.75m, with a maximum additional contingent consideration of £0.2m.

The sale of the division improves Quantum Pharma’s EBITDA (earnings before interest, tax, depreciation and amortisation) margin by eliminating low-margin turnover. In addition, the company’s remaining divisions have traded ahead of expectations in the early months of the year. The company expects this to offset the majority of the disposed contribution from Biodose Services in the current year.

Looking ahead, Quantum Pharma is expected to report a rise in its bottom line of 31% in the next financial year. Even after today’s 3%+ rise in its share price, this leaves the business trading on a price-to-earnings growth (PEG) ratio of just 0.4. This suggests its capital growth potential is high, which means it may be worth buying for the long term.

Growth potential

Also offering a wide margin of safety at the present time is sector peer Vectura (LSE: VEC). The therapeutic products and drug delivery systems specialist has a strong track record of growth. For example, in the last three years it has been able to increase its bottom line at an annualised rate of around 70%. This shows that its strategy has been working well.

Its future growth rate is also highly impressive. The company is forecast to report a rise in its bottom line of 54% next year, which could help to improve investor sentiment after a share price decline of 25% in the last year. One consequence of a disappointing year for its share price is that Vectura now trades on a PEG ratio of 0.3. This indicates that it could offer significant capital growth potential, with a margin of safety present in case there are downgrades to its forecasts.

Clearly, Vectura is a small company which may offer relatively high risks. However, with a substantial discount to its intrinsic valuation it could prove to be a sound long-term buy for less risk-averse investors.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of Vectura Group. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »